Reader TTS

As it becomes clear that the London clinical trial disaster was indeed the fault of the drug itself, Michael Hopkin looks at what went wrong, and whether there is any future for

‘superagonist’ antibody therapies. Access through your institution Buy or subscribe This is a preview of subscription content, access via your institution ACCESS OPTIONS Access through your

institution Subscribe to this journal Receive 51 print issues and online access $199.00 per year only $3.90 per issue Learn more Buy this article * Purchase on SpringerLink * Instant access

to full article PDF Buy now Prices may be subject to local taxes which are calculated during checkout ADDITIONAL ACCESS OPTIONS: * Log in * Learn about institutional subscriptions * Read our

FAQs * Contact customer support RELATED LINKS RELATED LINKS RELATED LINKS IN NATURE RESEARCH Drug to blame for clinical-trial disaster? British trial disaster casts doubts on testing

guidelines London's disastrous drug trial has serious side effects for research Tragic drug trial spotlights potent molecule Health and medicine news Cell and molecular biology news

Policy news RELATED EXTERNAL LINKS TeGenero trial FAQs Parexel, US trial conductors Drug manufacturer Boehringer Ingelheim's comment Northwick Park Hospital updates Medicines and Health

care Regulations Agency (MEHA) Academy of Medical Sciences RIGHTS AND PERMISSIONS Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Can super-antibody drugs be tamed?. _Nature_

440, 855–856 (2006). https://doi.org/10.1038/440855a Download citation * Published: 12 April 2006 * Issue Date: 13 April 2006 * DOI: https://doi.org/10.1038/440855a SHARE THIS ARTICLE Anyone

you share the following link with will be able to read this content: Get shareable link Sorry, a shareable link is not currently available for this article. Copy to clipboard Provided by

the Springer Nature SharedIt content-sharing initiative